title: Effect of β-cyclodextrin complexation on solubility and enzymatic hydrolysis rate of icariin.
abstract: OBJECTIVE
  The aim of this work was to investigate the effect of β-cyclodextrin complexation on the solubility and hydrolysis rate of icariin.
  
  
  METHODS
  The inclusion complex of icariin at the molar ratio of 1:1 was obtained by the dropping method and was characterized by differential scanning calorimetry. The solubility of icariin complex in water at 37°C was 36 times greater than that of free icariin. Enzymatic hydrolysis conditions were tested for the bioconversion of icariin by mono-factor experimental design.
  
  
  METHODS
  The inclusion complex of icariin at the molar ratio of 1:1 was obtained by the dropping method and was characterized by differential scanning calorimetry. The solubility of icariin complex in water at 37°C was 36 times greater than that of free icariin. Enzymatic hydrolysis conditions were tested for the bioconversion of icariin by mono-factor experimental design.
  
  
  RESULTS
  The enzymatic hydrolysis experiment showed that icariin can be transformed into baohuoside I. The optimum conditions determined were as follows: pH 5.0, 50°C, the ratio of cellulase/substrate (0.6), the concentration of icariin 20 mg/ml, and reaction time 12 h. Under these enzymatic conditions, 98.2% transforming rate of baohuoside I from icariin in inclusion complexes was obtained.
  
  
  CONCLUSIONS
  The aqueous solubility and enzymatic hydrolysis rate of icariin were improved owing to the inclusion complexation.
authors: Jiangsu Provincial Academy of Chinese Medicine, Jiangsu, China.
authors: Li
authors: L
authors: Cui
authors: Zhenhai
authors: Z
authors: Zhang
authors: E
authors: E
authors: Sun
authors: Xiaobin
authors: X
authors: Jia
authors: Qian
authors: Q
authors: Qian
keywords: Baohuoside I; enzymolysis; icariin; inclusion complex; β-cyclodextrin
references: Biochim Biophys Acta. 2000 Dec 29;1543(2):239-252
references: 11150609
references: J Pharm Biomed Anal. 2007 Nov 5;45(3):480-6
references: 17822867
references: Planta Med. 2000 Mar;66(2):114-8
references: 10763582
references: J Control Release. 2008 Feb 18;126(1):17-25
references: 18079013
references: Transpl Immunol. 2005 Oct;15(1):55-62
references: 16223673
references: Enzyme Microb Technol. 2001 Apr 5;28(6):499-509
references: 11267644
references: J Pharm Sci. 2008 Oct;97(10):4319-35
references: 18288724
references: Eur J Pharmacol. 2008 Jan 28;579(1-3):58-65
references: 17980359
references: Evid Based Complement Alternat Med. 2005 Sep;2(3):353-61
references: 16136213
references: Fitoterapia. 2010 Jul;81(5):437-42
references: 20026390
references: Biotechnol Adv. 2002 Dec;20(5-6):341-59
references: 14550020
references: Planta Med. 2000 Mar;66(2):119-23
references: 10763583
references: Life Sci. 2007 Aug 16;81(10):832-40
references: 17764702
references: J Control Release. 2007 Nov 6;123(2):78-99
references: 17888540
references: Drug Dev Ind Pharm. 1999 Dec;25(12):1241-8
references: 10612019
references: Eur J Pharmacol. 2011 Mar 1;654(1):10-6
references: 21172343
references: Bioresour Technol. 2007 May;98(7):1366-72
references: 16822673